Regenerate artifacts from biolink-model.yaml

project/jsonld/biolink_model.context.jsonld

@@ -1,7 +1,7 @@
 {
    "comments": {
       "description": "Auto generated by LinkML jsonld context generator",
-      "generation_date": "2024-03-13T17:21:19",
+      "generation_date": "2024-03-21T20:30:39",
       "source": "biolink_model.yaml"
    },
    "@context": {

project/jsonld/biolink_model.jsonld

@@ -7820,7 +7820,7 @@
           "@type": "Annotation"
         }
       ],
-      "description": "Holds between an intervention (substance, procedure, or activity) and a medical condition (disease or phenotypic feature), and states that the intervention is able to ameliorate, stabilize, or cure the condition or delay, prevent, or reduce the risk of it manifesting in the first place. \u2018Treats\u2019 edges should be asserted (knowledge_level: assertion) only in cases where there is strong supporting evidence - i.e. the intervention is approved or in phase 4 trials for the condition, or is an otherwise established treatment in the medical community (e.g. a widely-accepted or formally recommended off-label use). In the absence of such evidence, weaker predicates should be used in asserted edges (e.g. \u2018in clinical trials for\u2019 or \u2018beneficial in models of\u2019). \u2018Treats\u2019 edges based on weaker or indirect forms of evidence can however be created as predictions (knowledge_level: prediction) and should point to the more foundational asserted edges that support them.",
+      "description": "Holds between an intervention (substance, procedure, or activity) and a medical condition (disease or phenotypic feature), and states that the intervention is able to ameliorate, stabilize, or cure the condition or delay, prevent, or reduce the risk of it manifesting in the first place. \u2018Treats\u2019 edges should be asserted (knowledge_level: assertion) only in cases where there is strong supporting evidence - i.e. the intervention is approved for the condition, passed phase 3 or in phase 4 trials for the condition, or is an otherwise established  treatment in the medical community (e.g. a widely-accepted or formally recommended  off-label use). In the absence of such evidence, weaker predicates should be used in  asserted edges (e.g. \u2018in clinical trials for\u2019 or \u2018beneficial in models of\u2019). \u2018Treats\u2019 edges based on weaker or indirect forms of evidence can however be created as predictions  (knowledge_level: prediction) and should point to the more foundational asserted edges that  support them.",
       "in_subset": [
         "translator_minimal"
       ],
@@ -34644,9 +34644,9 @@
   ],
   "metamodel_version": "1.7.0",
   "source_file": "biolink_model.yaml",
-  "source_file_date": "2024-03-13T17:21:14",
-  "source_file_size": 391934,
-  "generation_date": "2024-03-13T17:21:21",
+  "source_file_date": "2024-03-21T20:30:34",
+  "source_file_size": 391979,
+  "generation_date": "2024-03-21T20:30:41",
   "@type": "SchemaDefinition",
   "@context": [
     "project/jsonld/biolink_model.context.jsonld",

src/biolink_model/datamodel/model.py

@@ -1,5 +1,5 @@
 # Auto generated from biolink_model.yaml by pythongen.py version: 0.0.1
-# Generation date: 2024-03-13T17:21:44
+# Generation date: 2024-03-21T20:31:05
 # Schema: Biolink-Model
 #
 # id: https://w3id.org/biolink/biolink-model

src/biolink_model/schema/biolink_model.yaml

@@ -3469,13 +3469,14 @@ slots:
       stabilize, or cure the condition or delay, prevent, or reduce the risk of it manifesting
       in the first place.
       ‘Treats’ edges should be asserted (knowledge_level: assertion) only in cases where there
-      is strong supporting evidence - i.e. the intervention is approved or in phase 4 trials for
-      the condition, or is an otherwise established treatment in the medical community (e.g. a
-      widely-accepted or formally recommended off-label use). In the absence of such evidence,
-      weaker predicates should be used in asserted edges (e.g. ‘in clinical trials for’ or
-      ‘beneficial in models of’). ‘Treats’ edges based on weaker or indirect forms of evidence
-      can however be created as predictions (knowledge_level: prediction) and should point to
-      the more foundational asserted edges that support them.
+      is strong supporting evidence - i.e. the intervention is approved for the condition, passed
+      phase 3 or in phase 4 trials for the condition, or is an otherwise established 
+      treatment in the medical community (e.g. a widely-accepted or formally recommended 
+      off-label use). In the absence of such evidence, weaker predicates should be used in 
+      asserted edges (e.g. ‘in clinical trials for’ or ‘beneficial in models of’). ‘Treats’ edges
+      based on weaker or indirect forms of evidence can however be created as predictions 
+      (knowledge_level: prediction) and should point to the more foundational asserted edges that 
+      support them.
     domain: chemical or drug or treatment
     range: disease or phenotypic feature
     annotations:

src/biolink_model/scripts/classprefixes.py

@@ -1,5 +1,5 @@
 # Auto generated from class_prefixes.yaml by pythongen.py version: 0.0.1
-# Generation date: 2024-03-13T17:23:10
+# Generation date: 2024-03-21T20:32:30
 # Schema: BiolinkClassPrefixes
 #
 # id: biolink-model-class-prefixes